IPSEN (IPSEY) Stock Price, News & Analysis

Company Overview

Ipsen S.A. is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer. Ipsen also markets treatments for rare cholestatic liver diseases, including Bylvay, and has additional products and development programs in cancer and specialty care.

Founded in France in 1929, Ipsen has expanded internationally through internal research, licensing agreements and acquisitions. The company serves patients and healthcare providers across Europe, North America and other global markets. Ipsen is headquartered in Paris, France, and is led by Chief Executive Officer David Loew.

Key Stats

• Today's Range: $42.25 to $42.75
• 50-Day Range: $39.75 to $49.15
• 52-Week Range: $34.34 to $51.10
• Volume: 11,208 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

IPSEN Stock Analysis - MarketRank™

IPSEN scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

IPSEN has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

IPSEN has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 5.50%

Earnings Growth

Earnings for IPSEN are expected to grow by 5.50% in the coming year, from $3.82 to $4.03 per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of IPSEN has been sold short.

Short Interest Ratio / Days to Cover

IPSEN has a short interest ratio ("days to cover") of 0.11, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IPSEN has recently decreased by 57.50%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IPSEN does not currently pay a dividend.

Dividend Growth

IPSEN does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.62

News Sentiment

IPSEN has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for IPSEN this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added IPSEN to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IPSEN insiders have not sold or bought any company stock.

Percentage Held by Institutions

IPSEN has minimal institutional ownership at this time.

Company Calendar

• Today: 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:IPSEY
• CIK: N/A
• Web: www.ipsen.com
• Phone: (315) 833-5000
• Fax: 33-01-58-33-50-01
• Employees: 5,535
• Year Founded: 1929

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A